Acute graft-versus-host disease (GVHD) is seen in 20-80% of marrow-or blood-derived haematopoietic stem cell allograft recipients, and chronic GVHD in 30-60% of those surviving beyond day 100. [1] [2] [3] [4] [5] GVHD is a major cause of morbidity and mortality after allogeneic haematopoietic stem cell transplantation, and is directly or indirectly responsible for death in over half of the patients who experience treatment-related mortality. Patients with acute leukaemia who are alive and well 2 years after an allograft have a significantly higher risk of continued treatmentrelated mortality, and poorer survival in the presence of chronic GVHD requiring immunosuppressive therapy. 6 This results from a number of factors including infections and secondary malignancies. 7, 8 The treatment of chronic GVHD is difficult. Cyclosporine, prednisone, and azathioprine have been the main agents used with variable success rates. The combination of cyclosporine and prednisone used for high-risk chronic GVHD results in a response rate of 30-40%. 9 The addition of azathioprine in standard-risk patients has been associated with adverse outcome. 10 While none of the newer drugs has activity that is consistently superior to cyclosporine-prednisone, alternative drugs have been found to be useful in certain situations. 11 Thalidomide was developed as a sedative-hypnotic drug, but the development of severe foetal malformation led to withdrawal of its use from clinical practice. 12 Its diverse effects on the immune system and the cytokine cascade resulted in continued exploration of the drug in various disorders. 12 Initial murine data showed that the drug was active in acute GVHD, 13 and subsequent human data showed it to be active in acute 14 as well as chronic GVHD. [15] [16] [17] While questions have been raised about its activity in chronic GVHD in a recent blinded, placebocontrolled study, 18 most phase II reports show that the drug does possess some activity in GVHD. [19] [20] [21] [22] [23] Our preliminary impression of thalidomide was that it controlled chronic GVHD in a proportion of patients with haematological malignancies without increasing relapse 24 perhaps in some way secondary to its antimalignancy activity. 12, 25 We have now undertaken a formal retrospective analysis of our data to see if this impression is accurate.
Patients and methods
Comprehensive, prospectively gathered data 26 on 80 allograft recipients treated with thalidomide for acute (n ¼ 21) or chronic (n ¼ 59) GVHD at the Royal Marsden Hospital were reviewed. Patient characteristics are shown in Table 1 . Conditioning regimens used were standard and varied with the disease. All patients and donors provided informed consent for the procedure, and all research protocols were approved by the institutional review board.
GVHD prophylaxis
Cyclosporine was started at a dose of 3 mg/kg/day intravenously on day À1 and was switched to the oral route when mucositis resolved. Oral cyclosporine was started at a dose of 12.5 mg/kg/day in two divided doses. The dose was gradually tapered after day 50 at the rate of 5%/week with the aim of stopping the drug on day +180. Methotrexate, when used, was given at a dose of 15 mg/m 2 on day +1 and 10 mg/m 2 on days +3, +6, and +11. Unless there was significant liver or kidney dysfunction, methotrexate doses were not modified or omitted.
Supportive care
All patients were nursed in positive-pressure HEPA-filtered single rooms. Patients received oral nonabsorbable antibiotics. Prophylactic growth factors were not administered routinely. Neutropenic fever was treated with broadspectrum antimicrobial agents according to the prevalent institutional guidelines. All blood products were irradiated to 2500 cGy. All patients received Pneumocystis prophylaxis with oral trimethoprim-sulphamethoxazole or inhaled pentamidine. Patients with chronic GVHD received penicillin V for pneumococcal prophylaxis. 7 Grading and staging of GVHD Acute 27 and chronic 28, 29 GVHD were graded and staged according to standard previously published criteria. Chronic GVHD was considered de novo if it was not preceded by acute GVHD, progressive if it evolved from acute GVHD, and quiescent if there was a period without GVHD between acute and chronic GVHD.
Treatment of GVHD
Patients with acute GVHD were initially treated with highdose intravenous methylprednisolone (10-20 mg/kg/day) for at least 3 days. Further therapy was continued according to the clinical response. All patients also continued cyclosporine during the therapy of acute GVHD.
Patients developing chronic GVHD after stopping cyclosporine were recommenced on the drug. All patients were initially also treated with oral prednisone (1-5 mg/kg/ day). Other drugs such as azathioprine, tacrolimus (substituted for cyclosporine) and mycophenolate mofetil were added if there was no improvement.
Thalidomide therapy
Thalidomide was started at a dose of 50-100 mg thrice a day. The dose was gradually increased to reduce the severity of the side effects with the aim of administering a total daily dose of 600-1200 mg. The dose was adjusted according to patient tolerance, and clinical signs and symptoms of GVHD. Patients continued all the immunosuppressive agents they were already receiving. Four patients with severe pulmonary involvement were treated with the combination of thalidomide, tacrolimus, prednisone and azathioprine (four-drug therapy) as first-line therapy.
Response evaluation
Standard response criteria 28, 30 were used to evaluate response. Complete response (CR) was defined as complete resolution of clinical signs, no new organ involvement, and normal performance status. Partial response (PR) was defined as improvement in the performance status of at least two orders and at least 50% resolution of signs and symptoms of disease. No response (NR) was defined as lack of improvement within 3 months or progression of disease on therapy.
Statistical methods
The probabilities of survival and mortality were determined using the Kaplan-Meier life-table method. The percentage of patients responding to thalidomide was compared using the Wilcoxon rank-sum test.
Results

Acute GVHD
The median time to development of acute GVHD was 11 days (range 9-40). Skin was involved in all, liver in 13 and gut in 19. In addition to high-dose methylprednisolone and cyclosporine, patients also received a murine anti-IL2 receptor antibody (n ¼ 5), azathioprine (n ¼ 2), Campath-1G (n ¼ 2), methotrexate (n ¼ 2), total-lymphoid irradiation (n ¼ 1) and antithymocyte globulin (n ¼ 1). All patients had progressive GVHD, with no response to the first-or second-line therapy. The overall Glucksberg grade at the time of starting thalidomide was III in 11 and IV in 10.
Thalidomide was started at a median of 48 days (range 13-84) after the transplant, and the median duration of treatment was 16.5 days (range 1-70). No patient responded, and all died of progressive GVHD at a median of 69 days (range 23-118 days) after the allograft (Figure 1 ).
Chronic GVHD
In all, 10 of the patients (Table 1) were treated for chronic GVHD that had developed following cell-mediated immunotherapy of relapsed disease with donor leucocytes.
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The remainder were treated for chronic GVHD developing after the transplant. Table 2 shows the organs involved, Table 3 the severity of the process and Table 4 the mode of onset. The initial therapy of chronic GVHD consisted of prednisolone and cyclosporine in all the patients. In total, 39 patients also received azathioprine at some stage. Of which, 14 patients responded to first-line therapy partly before experiencing progressive GVHD.
Thalidomide was started at a median of 385 days (range, 92-3432) post-transplant. The median duration of therapy was 61 days (range, 1-1210), and the median daily dose 400 mg (range, 50-1200). The 11 patients receiving therapy for o2 weeks, most because of excessive sedation, were considered non-responders. As expected, the duration of therapy for CR patients (median 196 days; range 30-721) was longer than that for PR (median 120 days; range 14-337) and NR (median 39 days; range 1-1210) (P ¼ 0.005). Figure 1 shows response. CR was seen in 13 (22%), eight had PR (14%), and 38 (64%) did not respond. The overall response rate was 36%. As Tables 3 and 4 show, the extent of the disease or the mode of onset did not affect response rates. There was no correlation between response to thalidomide and response to previous therapy. There was no correlation between any type of organ involvement and response to thalidomide. Five of the 14 patients with lung GVHD responded to therapy (three CR and two PR). Figure 1 summarizes the outcome. A total of 19 patients are alive at a median of 53 months (range, 5-159) post transplant. The median Karnofsky performance score is 80% (range, 70-100%). The actuarial 5-year probability of survival is 37% (95% CI: 23-51%) (Figure 2 ). In all, 12 patients are alive without chronic GVHD, and seven with.
Response in chronic GVHD
The causes of death were chronic GVHD (n ¼ 29), relapsed leukaemia (n ¼ 7), secondary malignancy (n ¼ 2), Response by the mode of onset of chronic GVHD (P=0.8)
idiopathic pneumonitis (n ¼ 1), and myocardial infarction (n ¼ 1). A significantly higher proportion of responding patients survived compared to non-responders (14 of 21 vs 5 of 38; Po0.0001; Figure 3 ). Of the 10 patients who received thalidomide for chronic GVHD following cell-mediated immunotherapy, two had CR, two PR and six NR. Two patients who achieved CR are alive one off immunosuppression and one with active GVHD. Both with PR died of relapsed leukaemia. One with NR is alive with extensive chronic GVHD on immunosuppression (including thalidomide), three died of GVHD, and two died of relapsed leukaemia. Leukaemia relapsed in two out of 21 patients who responded to thalidomide as compared to three out of 38 who did not respond. Two relapses occurred among patients who were treated successfully for chronic GVHD that had appeared primarily because of the allograft (as opposed to immunotherapy-induced GVHD).
Toxicity
Thalidomide was generally well tolerated. Sedation, dizziness and constipation were common. Symptoms of peripheral neuropathy (n ¼ 2) and deep vein thrombosis (n ¼ 2) were uncommon. One patient with a normal blood count at the start of therapy developed thrombocytopenia that recovered spontaneously on discontinuation of thalidomide.
Discussion
Our data show that thalidomide is ineffective in steroidrefractory acute GVHD, but is effective in a proportion of patients with chronic GVHD when used in combination with cyclosporine and prednisone (with or without additional immunosuppressive agents). Response of chronic GVHD to thalidomide therapy is associated with better survival.
The efficacy and potential of thalidomide as a single agent in the treatment of GVHD is undefined. Indeed, because of the difficulty in deviating from established immunosuppressive therapy (making thalidomide monotherapy difficult), the length of time often required to treat chronic GVHD, and the often-fluctuating clinical course of chronic GVHD make the determination of its activity challenging. Indeed, the only controlled study evaluating its use in chronic GVHD found the drug to be inactive. 18 Thalidomide possesses a number of anti-inflammatory and immunomodulatory properties, which may underlie its activity in GVHD. 12 These have been discussed in detail elsewhere, 12, 33 and include inhibition of tumour necrosis factor-a (TNF-a), IL-6, IL-10, and IL-12 production, increase in IL-2, IL-4 and IL-5 production, modulation of interferon-g production, increase in total lymphocyte counts as well as CD4+ and CD8+ T cells, and costimulation of T lymphocytes. It also inhibits angiogenesis and alters adhesion molecule expression. 12 Whether the lack of effect of thalidomide in acute GVHD is related to the speed of development of acute GVHD or the difference in the immunological mechanism involved in its pathogenesis (compared to chronic GVHD) is not known. It may be the latter in view of some of the paradoxical effects the drug has (vide supra) because, when used for GVHD prophylaxis, it has been shown to increase acute GVHD. 34 It is also possible that optimum duration of therapy necessary for any potential benefit will not be achieved due to the rapidity of progression of severe acute GVHD.
There is some suggestion that thalidomide may have particular activity in pulmonary chronic GVHD. 35 This is certainly plausible because angiogenesis underlies fibrosis, and thalidomide inhibits angiogenesis. We did not find any strong relation between response to thalidomide and the nature of organ involvement; five of 14 patients with lung involvement in our series responded to thalidomide with disappearance of symptoms and improvement in pulmonary function studies. The extent (severity) or mode of onset of chronic GVHD did not influence the response rate. Vogelsang et al 17 reported higher response rate with thalidomide for refractory disease as compared to primary therapy of high-risk disease, whereas Parker et al 20 found similar response rate in high risk and standard risk GVHD. Thalidomide after allo-HSCT S Kulkarni et al
We conclude that thalidomide holds some promise for the treatment of refractory chronic GVHD, and if successful, may improve survival. Since drug intolerance is an important factor resulting in early discontinuation of therapy, its analogues such as CC5013 36 may improve response rates through better tolerance.
